WallStSmart
ZURA

Zura Bio Limited Class A Ordinary Shares

NASDAQ: ZURA · HEALTHCARE · BIOTECHNOLOGY

$4.75
-7.36% today

Updated 2026-06-05

Market cap
$351.06M
P/E ratio
P/S ratio
EPS (TTM)
$-1.09
Dividend yield
52W range
$1 – $7
Volume
0.8M

Zura Bio Limited Class A Ordinary Shares (ZURA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20212022202320242025
Revenue$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$9000.00$49000.00
Gross profit$-9000.00$-49000.00
Gross margin
R&D$23.69M$44.00M$24.40M$42.08M
SG&A$3.47M$18.64M$30.79M$33.16M
Operating income$-1.09M$-27.16M$-62.64M$-55.19M$-75.25M
Operating margin
EBITDA$8.42M$-27.16M$-62.64M$-55.18M$-75.20M
EBITDA margin
EBIT$8.42M$-27.33M$-60.56M$-55.19M$-75.25M
Interest expense
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%
Net income$8.42M$-25.74M$-60.36M$-52.40M$-68.65M
Net income growth (YoY)-405.8%-134.5%+13.2%-31.0%
Profit margin

Frequently asked questions

How much free cash flow does ZURA generate?

ZURA produced $-64.93M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ZURA's balance sheet healthy?

ZURA holds $109.41M in cash and equivalents against — in long-term debt, on $101.54M of shareholder equity. That debt is best read against the cash flow the business throws off each year.